| Company Name: |
Zhengzhou Granlen Sciences, ltd.
|
| Tel: |
0371-85513397 +86-18610099868 |
| Email: |
info@granlen.com |
| Products Intro: |
Product Name:7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine
CAS:2389988-25-2
Purity: 95% HPLC Package:根据客户需要包装 Remarks:GL102252
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:7-Allyl-7,8-dihydro-8-oxo-9-(b-D-xylofuranosyl) ? guanine
CAS:2389988-25-2
Package:5mg;10mg;25mg
|
| Company Name: |
Shanghai meikai technology co., ltd
|
| Tel: |
021-68689288 15300790979 |
| Email: |
info@mkbio.com.cn |
| Products Intro: |
Product Name:7-allyl-2-amino-9-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7,9-dihydro-1H-purine-6,8-dione
CAS:2389988-25-2
Purity:98% Package:100mg;250mg;1g
|
7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine manufacturers
|
| | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine Basic information |
| Product Name: | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine | | Synonyms: | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine;7-Allyl-7,8-dihydro-8-oxo-9-(b-D-xylofuranosyl)guanine;7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine;1H-Purine-6,8-dione, 2-amino-7,9-dihydro-7-(2-propen-1-yl)-9-β-D-xylofuranosyl-;7-allyl-2-amino-9-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7,9-dihydro-1H-purine-6,8-dione | | CAS: | 2389988-25-2 | | MF: | C13H17N5O6 | | MW: | 339.3 | | EINECS: | | | Product Categories: | | | Mol File: | 2389988-25-2.mol |  |
| | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine Chemical Properties |
| Boiling point | 591.8±60.0 °C(Predicted) | | density | 1.92±0.1 g/cm3(Predicted) | | pka | 13.39±0.70(Predicted) |
| | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine Usage And Synthesis |
| Uses | 7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 7-Allyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl) guanine Preparation Products And Raw materials |
|